Skip to main content

MDxHealth SA (MDXH)

NASDAQ: MDXH · IEX Real-Time Price · USD
9.43 0.39 (4.30%)
Nov 29, 2021 10:14 AM EST - Market open

Company Description

MDxHealth is a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care.

Our novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications.

Our unique approach combines advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., Prostate Specific Antigen, digital rectal exam, age) used by clinicians.

Our lead products address men at risk for developing prostate cancer, but in addition, we are actively developing testing solutions to help with the management of men diagnosed with prostate cancer, with the goal to provide our clients with a menu of tools spanning the continuum of prostate cancer diagnosis and care.

MDxHealth SA
CountryBelgium
Founded2003
IPO DateNov 4, 2021
IndustryDiagnostics & Research
SectorHealthcare
Employees177
CEOJan Groen

Contact Details

Address:
CAP Business Center
Herstal, Liege 4040
Belgium
Phone3242577021
Websitemdxhealth.com

Stock Details

Ticker SymbolMDXH
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$13.46
CIK Code1872529

Key Executives

NamePosition
Koen HoffmanIndependent Non-Executive Director (Chairperson of the Board of Directors)
Michael K. McGarrityExecutive Director (Chief Executive Officer)
Rudi MariënNon-Executive Director
Jan PensaertNon-Executive Director
Dr. Lieve VerplanckeIndependent Non-Executive Director
Hilde WindelsIndependent Non-Executive Director
Dr. Regine SlagmulderIndependent Non-Executive Director
Dr. Eric BednarskiNon-Executive Director

Latest SEC Filings

DateTypeTitle
Nov 23, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 15, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 12, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 9, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 5, 2021424B4Prospectus [Rule 424(b)(4)]
Nov 4, 2021EFFECTNotice of Effectiveness
Nov 3, 2021CERTCertification by an exchange approving securities for listing
Nov 1, 20218-A12BRegistration of securities [Section 12(b)]
Nov 1, 2021F-1/ARegistration statement for certain foreign private issuers
Oct 27, 2021F-1/ARegistration statement for certain foreign private issuers
View All SEC Filings